Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Positive
- None.
Negative
- None.
News Market Reaction – CLLS
On the day this news was published, CLLS gained 5.00%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, April 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 03/31/2025 | 100,290,078 | 89,046,759 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
What is the total number of Cellectis (CLLS) shares as of March 31, 2025?
How many voting rights does Cellectis (CLLS) have as of March 2025?
What is the difference between Cellectis (CLLS) total shares and voting rights in March 2025?
On which exchange is Cellectis (CLLS) stock listed according to the March 2025 report?